Serial Number 97004685
602

Registration Progress

Application Filed
Aug 31, 2021
Under Examination
Approved for Publication
Published for Opposition
Registered

Basic Information

Serial Number
97004685
Filing Date
August 31, 2021
Abandonment Date
December 5, 2022
Drawing Code
2000

Status Summary

Current Status
Inactive
Status Code
602
Status Date
Dec 20, 2022
Classes
044

Rights Holder

Cytotheryx, Inc.

03
Address
PO Box 7193
Rochester, MN 55903

Ownership History

Cytotheryx, Inc.

Original Applicant
03
Rochester, MN

Legal Representation

Attorney
Cynthia A. Moyer
USPTO Deadlines
Next Renewal Deadline
Non-Final Action E-Mailed
Due: September 04, 2022 (1037 days overdue)
Extension available until: December 04, 2022
Additional renewal deadlines exist. Contact your attorney for complete deadline information.

Application History

14 events
Date Code Type Description
Dec 21, 2022 MAB2 E ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Dec 20, 2022 ABN2 O ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Dec 20, 2022 MAB2 O ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Jun 4, 2022 DOCK D ASSIGNED TO EXAMINER
Jun 4, 2022 CNRT R NON-FINAL ACTION WRITTEN
Jun 4, 2022 GNRT F NON-FINAL ACTION E-MAILED
Jun 4, 2022 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 20, 2021 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 20, 2021 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 20, 2021 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 20, 2021 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 20, 2021 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 15, 2021 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED
Oct 14, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

Detailed Classifications

Class 044
medical treatment, namely, administering gene therapies in the nature of in vivo and ex vivo vector treatments; medical treatment, namely, administering gene therapies in the nature of lentiviral vector therapies; medical treatment, namely, administering gene therapies in the nature of gene therapies for the treatment of rare diseases; medical treatment, namely, administering gene therapies in the nature of gene therapies for Hereditary Tyrosinemia Type 1; medical treatment, namely, administering gene therapies in the nature of gene therapies for orphan disease; medical treatment, namely, administering gene therapies in the nature of gene therapies for inborn errors of hepatic metabolism
First Use Anywhere: 0
First Use in Commerce: 0

Additional Information

Design Mark
The mark consists of stylized hands grasping a stylized image of a liver.
Color Claim
Color is not claimed as a feature of the mark.

Classification

International Classes
044